Evangeline B. Handog
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Evangeline B. Handog has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Dulce Amor Vivan F. Galang
From the Section of Dermatology, Research Institute for Tropical Medicine, Department of Health, Manila, Philippines
1 shared publicationGertrude P. Chan
From the Section of Dermatology, Research Institute for Tropical Medicine, Department of Health, Manila, Philippines
1 shared publicationMaria Azirrel De Leon‐Godinez
From the Section of Dermatology, Research Institute for Tropical Medicine, Department of Health, Manila, Philippines
1 shared publicationRosario Trinidad V Pineda
Philippine Dermatological Society, Philippines
1 shared publicationTeresita G. Gabriel
Research Institute for Tropical Medicine, Department of Health, Philippines
1 shared publicationTrisha C. Crisostomo
1 shared publication
Latest Publications
- 26 March 2010
- Published by Springer Nature
- p. 187-201
Nutrition, Vitamins, and Supplements
- 20 July 2009
- Published by Wiley in International Journal of Dermatology
- Vol. 48 (8) , 896-901
A randomized, double‐blind, placebo‐controlled trial of oral procyanidin with vitamins A, C, E for melasma among Filipino women
Background Melasma is a common, acquired, symmetric hypermelanosis characterized by irregular brown to gray–brown macules on the cheeks, forehead, nasal bridge, cutaneous part of the upper lip, mandible, and the upper arms. Few trials have been conducted regarding the potential benefits of oral procyanidin in melasma.Aim To assess the safety and efficacy of oral procyanidin + vitamins A, C, E among Filipino patients with epidermal melasma.Methods A randomized, double‐blind, placebo‐controlled trial lasting 8 weeks, involving 60 adult female volunteers with bilateral epidermal melasma, Fitzpatrick skin types III–V, was conducted at the Section of Dermatology, Research Institute for Tropical Medicine, Department of Health, Manila, Philippines. Patients received either the test drug or placebo, twice daily with meals. Changes in pigmentation were measured using a mexameter, the melasma area and severity index (MASI), and a global evaluation by the patient and investigator. Safety evaluations were performed at each follow‐up visit.Results Fifty‐six patients completed the trial. Mexameter results demonstrated a significant decrease in the degree of pigmentation in the left malar (165.85 ± 70.909) and right malar (161.33 ± 61.824) regions (P < 0.0001). MASI scores showed a significant improvement in the left malar (2.4862 ± 1.67816) and right malar (1.8889 ± 1.67110) regions (P = 0.001). Procyanidin + vitamins A, C, E proved to be safe and well tolerated, with minimal adverse events.Conclusions In this 8‐week trial period, oral procyanidin + vitamins A, C, E proved to be safe and effective among Filipino women with epidermal melasma.
- 20 July 2009
- Published by Wiley in International Journal of Dermatology
- Vol. 48 (8) , 896-901
A randomized, double‐blind, placebo‐controlled trial of oral procyanidin with vitamins A, C, E for melasma among Filipino women
Background Melasma is a common, acquired, symmetric hypermelanosis characterized by irregular brown to gray–brown macules on the cheeks, forehead, nasal bridge, cutaneous part of the upper lip, mandible, and the upper arms. Few trials have been conducted regarding the potential benefits of oral procyanidin in melasma.Aim To assess the safety and efficacy of oral procyanidin + vitamins A, C, E among Filipino patients with epidermal melasma.Methods A randomized, double‐blind, placebo‐controlled trial lasting 8 weeks, involving 60 adult female volunteers with bilateral epidermal melasma, Fitzpatrick skin types III–V, was conducted at the Section of Dermatology, Research Institute for Tropical Medicine, Department of Health, Manila, Philippines. Patients received either the test drug or placebo, twice daily with meals. Changes in pigmentation were measured using a mexameter, the melasma area and severity index (MASI), and a global evaluation by the patient and investigator. Safety evaluations were performed at each follow‐up visit.Results Fifty‐six patients completed the trial. Mexameter results demonstrated a significant decrease in the degree of pigmentation in the left malar (165.85 ± 70.909) and right malar (161.33 ± 61.824) regions (P < 0.0001). MASI scores showed a significant improvement in the left malar (2.4862 ± 1.67816) and right malar (1.8889 ± 1.67110) regions (P = 0.001). Procyanidin + vitamins A, C, E proved to be safe and well tolerated, with minimal adverse events.Conclusions In this 8‐week trial period, oral procyanidin + vitamins A, C, E proved to be safe and effective among Filipino women with epidermal melasma.
- 1 May 2008
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 21 (3) , 154-161
Management of cutaneous tuberculosis
Cutaneous tuberculosis (TB) is an extrapulmonary form of tuberculosis, which may be classified based on the immunologic state of the host. Chemotherapy still remains the treatment of choice. The management of cutaneous TB follows the same guidelines as that of TB of other organs, which can be treated with a short course four-agent chemotherapeutic regimen given for 2 months followed by a two-drug regimen for the next 4 months. This chapter highlights current treatment recommendations for cutaneous TB. The important factors to consider in the choice of optimal treatment includes the type of cutaneous involvement, stage of the disease, level of immunity, and general condition of the patient. The highest priority in any cutaneous TB control program is the proper, accurate, and rapid detection of cases and the availability of chemotherapy to all tuberculosis patients until cure. Contact tracing is also an important component of efficient tuberculosis control.
- 1 May 2008
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 21 (3) , 154-161
Management of cutaneous tuberculosis
Cutaneous tuberculosis (TB) is an extrapulmonary form of tuberculosis, which may be classified based on the immunologic state of the host. Chemotherapy still remains the treatment of choice. The management of cutaneous TB follows the same guidelines as that of TB of other organs, which can be treated with a short course four-agent chemotherapeutic regimen given for 2 months followed by a two-drug regimen for the next 4 months. This chapter highlights current treatment recommendations for cutaneous TB. The important factors to consider in the choice of optimal treatment includes the type of cutaneous involvement, stage of the disease, level of immunity, and general condition of the patient. The highest priority in any cutaneous TB control program is the proper, accurate, and rapid detection of cases and the availability of chemotherapy to all tuberculosis patients until cure. Contact tracing is also an important component of efficient tuberculosis control.